Antibody Responses to Respiratory Syncytial Virus: A Cross-Sectional Serosurveillance Study in the Dutch Population Focusing on Infants Younger Than 2 Years

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2020 Sep 23

PMID 32964923

Citations 24

Authors

Guy Berbers

Liesbeth Mollema

Fiona van der Klis

Gerco Den Hartog

Rutger Schepp

Affiliations

Soon will be listed here.

Abstract

Background: Respiratory syncytial virus (RSV) generally causes mild disease but can cause severe infections in (premature) infants and elderly adults. Here, we studied RSV-specific antibody concentrations throughout life with emphasis on infants and chronic obstructive pulmonary disease (COPD) patients.

Methods: Sera (N = 2655) from 2 nationwide cross-sectional studies in the Netherlands including individuals aged 0-90 years were analyzed for IgG and IgA antibodies to RSV prefusion F, postfusion F, N, Ga, and Gb proteins and for antibody avidity in 42 COPD patients.

Results: Maternal IgG concentrations declined to age 10-12 months. After the first year of life, approximately 40% of children lacked infection-induced IgA antibodies and may therefore be uninfected. All Dutch children showed serological evidence of RSV infection by age 3 years. Antibody concentrations reached a plateau by age 5-9 years and remains constant throughout life. COPD patients had similar levels and avidity of RSV-specific IgG antibodies compared with age-matched healthy controls.

Conclusions: RSV-IgG antibody patterns throughout life can be used to estimate the degree of immunity acquisition to RSV and to identify groups at increased risk of infection. Seroprevalence of IgA could be a proxy to determine RSV infection in children younger than 1 year.

Citing Articles

Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options.

Ricco M, Abu-Raya B, Icardi G, Spoulou V, Greenberg D, Pecurariu O Vaccines (Basel). 2025; 12(12.

PMID: 39771979 PMC: 11679680. DOI: 10.3390/vaccines12121317.

Antibody-mediated protection against respiratory syncytial virus in children.

Coindy E, Efstathiou C, Talwar S, Moureau A, Vernhes C, Openshaw P Eur Respir Rev. 2024; 33(174).

PMID: 39384305 PMC: 11462297. DOI: 10.1183/16000617.0106-2024.

Impact of COVID-19 Nonpharmaceutical Interventions on , Human Respiratory Syncytial Virus, Influenza Virus, and Seasonal Coronavirus Antibody Levels: A Systematic Review.

Gaasbeek C, Visser M, de Vries R, Koopmans M, van Binnendijk R, Den Hartog G Open Forum Infect Dis. 2024; 11(10):ofae518.

PMID: 39347437 PMC: 11430909. DOI: 10.1093/ofid/ofae518.

Postpandemic fluctuations of regional respiratory syncytial virus hospitalization epidemiology: potential impact on an immunization program in Switzerland.

Fischli K, Schobi N, Duppenthaler A, Casaulta C, Riedel T, Kopp M Eur J Pediatr. 2024; 183(12):5149-5161.

PMID: 39331153 PMC: 11527947. DOI: 10.1007/s00431-024-05785-z.

How Does the Burden of Respiratory Syncytial Virus Compare to Influenza in Spanish Adults?.

Martinon-Torres F, Gutierrez C, Caceres A, Weber K, Torres A Influenza Other Respir Viruses. 2024; 18(6):e13341.

PMID: 38923767 PMC: 11194680. DOI: 10.1111/irv.13341.

References

Hall C, Long C, Schnabel K . Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis. 2001; 33(6):792-6. DOI: 10.1086/322657. View

Bagga B, Cehelsky J, Vaishnaw A, Wilkinson T, Meyers R, Harrison L . Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults. J Infect Dis. 2015; 212(11):1719-25. DOI: 10.1093/infdis/jiv281. View

Graham B . Vaccine development for respiratory syncytial virus. Curr Opin Virol. 2017; 23:107-112. PMC: 5653266. DOI: 10.1016/j.coviro.2017.03.012. View

Zhang L, Peeples M, Boucher R, Collins P, Pickles R . Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol. 2002; 76(11):5654-66. PMC: 137037. DOI: 10.1128/jvi.76.11.5654-5666.2002. View

Tsutsumi H, Matsuda K, Yamazaki H, Ogra P, Chiba S . Different kinetics of antibody responses between IgA and IgG classes in nasopharyngeal secretion in infants and children during primary respiratory syncytial virus infection. Acta Paediatr Jpn. 1995; 37(4):464-8. DOI: 10.1111/j.1442-200x.1995.tb03356.x. View

Hall C, Simoes E, Anderson L . Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol. 2013; 372:39-57. DOI: 10.1007/978-3-642-38919-1_2. View

Smyth R, Openshaw P . Bronchiolitis. Lancet. 2006; 368(9532):312-22. DOI: 10.1016/S0140-6736(06)69077-6. View

Bonnelykke K, Vissing N, Sevelsted A, Johnston S, Bisgaard H . Association between respiratory infections in early life and later asthma is independent of virus type. J Allergy Clin Immunol. 2015; 136(1):81-86.e4. PMC: 7112259. DOI: 10.1016/j.jaci.2015.02.024. View

Malek A, Sager R, Kuhn P, Nicolaides K, Schneider H . Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol. 1996; 36(5):248-55. DOI: 10.1111/j.1600-0897.1996.tb00172.x. View

10.

Nair H, Nokes D, Gessner B, Dherani M, Madhi S, Singleton R . Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010; 375(9725):1545-55. PMC: 2864404. DOI: 10.1016/S0140-6736(10)60206-1. View

11.

Schepp R, de Haan C, Wilkins D, Layman H, Graham B, Esser M . Development and Standardization of a High-Throughput Multiplex Immunoassay for the Simultaneous Quantification of Specific Antibodies to Five Respiratory Syncytial Virus Proteins. mSphere. 2019; 4(2). PMC: 6483049. DOI: 10.1128/mSphere.00236-19. View

12.

Trento A, Rodriguez-Fernandez R, Gonzalez-Sanchez M, Gonzalez-Martinez F, Mas V, Vazquez M . The Complexity of Antibody Responses Elicited against the Respiratory Syncytial Virus Glycoproteins in Hospitalized Children Younger than 2 Years. Front Microbiol. 2017; 8:2301. PMC: 5702767. DOI: 10.3389/fmicb.2017.02301. View

13.

Verberk J, Vos R, Mollema L, van Vliet J, van Weert J, de Melker H . Third national biobank for population-based seroprevalence studies in the Netherlands, including the Caribbean Netherlands. BMC Infect Dis. 2019; 19(1):470. PMC: 6537387. DOI: 10.1186/s12879-019-4019-y. View

14.

de Sierra T, Kumar M, Wasser T, Murphy B, Subbarao E . Respiratory syncytial virus-specific immunoglobulins in preterm infants. J Pediatr. 1993; 122(5 Pt 1):787-91. DOI: 10.1016/s0022-3476(06)80027-2. View

15.

Hall C, Walsh E, Long C, Schnabel K . Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991; 163(4):693-8. DOI: 10.1093/infdis/163.4.693. View

16.

Graham B . Vaccines against respiratory syncytial virus: The time has finally come. Vaccine. 2016; 34(30):3535-41. PMC: 4912855. DOI: 10.1016/j.vaccine.2016.04.083. View

17.

Piedra P, Jewell A, Cron S, Atmar R, Glezen W . Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine. 2003; 21(24):3479-82. DOI: 10.1016/s0264-410x(03)00355-4. View

18.

Ogilvie M, Vathenen A, Radford M, Codd J, Key S . Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol. 1981; 7(4):263-71. DOI: 10.1002/jmv.1890070403. View

19.

Mohan A, Chandra S, Agarwal D, Guleria R, Broor S, Gaur B . Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology. 2010; 15(3):536-42. PMC: 7192224. DOI: 10.1111/j.1440-1843.2010.01722.x. View

20.

. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics. 1998; 102(3):531-7. View